What Does the Design of a CAR T-cell Therapy Say About Its Efficacy and Toxicity Profile?

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Selecting CAR T-cell Therapy for Patients With Late Relapsed Multiple Myeloma

What Does the Design of a CAR T-cell Therapy Say About Its Efficacy and Toxicity Profile?

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    Although multiple myeloma (MM) is largely incurable, the introduction of novel frontline regimens has significantly improved survival in recent years. Following successful application in other hematologic malignancies, chimeric antigen receptor (CAR) T-cell therapies are now demonstrating impressive results in triple class-exposed MM, along with unique immune-related toxicities that must be recognized early and promptly managed. With the approval of one B-cell maturation antigen (BCMA)-directed CAR T-cell therapy and more anticipated shortly, this program will seek to educate clinicians on differences in product composition and toxicity burden, the latest available efficacy and safety data from clinical trials, strategies for selection, sequencing, and toxicity management, and effective strategies for shared decision making and patient communication specific to the CAR T-cell approach. By participating in this education, clinicians will have the improved knowledge and competence they need to leverage anti-BCMA approaches to optimize the care of patients with MM that they encounter in clinical practice today and in the near future.

  • Target Audience

    This activity has been designed to meet the educational needs of Hematologists/Oncologists, nurses, pharmacists, and cell therapy experts, as well as other clinicians involved in the management of patients with multiple myeloma.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Describe differences in product composition and toxicity burden with current and emerging CAR T-cell therapies in multiple myeloma
    2. Apply recent clinical trial data to inform strategies for selecting and sequencing CAR T-cell therapy in relapsed and refractory multiple myeloma patients
    3. Identify unique toxicities seen with CAR T-cell therapies and individualize strategies to mitigate toxicity burden to ensure patient safety and optimize outcomes
    4. Apply effective strategies for shared decision-making and communication to improve patient-centered care and outcomes
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
    This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have reported relationships with ineligible companies:

    Noopur Raje, MD, chair for this educational event, is a contract researcher for Bluebird Bio; receives consulting fees from BMS, Janssen, Pfizer, Amgen, and Takeda; and is on the scientific advisory board for Caribou Bio, Immuneel, AbbVie, and Sanofi.   

    Adam D. Cohen, MD, faculty for this educational event, is a contract researcher for GSK, Janssen, Novartis, and Genentech; has a patent with Novartis; and receives consulting fees from GSK, Janssen, Genentech/Roche, BMS/Celgene, AstraZeneca, AbbVie, Pfizer, Ichnos, Takeda, Oncopeptides, Arcellx.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Instructions

    During the period 9/30/222 through 9/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.


  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 Sep 2023